title: Gardasil: Introducing the new human papillomavirus vaccine.
abstract: In 2006, the U.S. Food and Drug Administration (FDA) approved the first vaccine for prevention of cervical cancer based on the molecular biology of the disease. Gardasil (quadrivalent human papillomavirus [HPV] [types 6, 11, 16, and 18] recombinant vaccine, Merck & Co., Inc., Whitehouse Station, NJ) combats the common types of HPV responsible for cervical cancer precursor lesions. This article provides a simple overview of the (a) epidemiology of HPV, (b) HPV vaccine, (c) dosing and administration, and (d) nursing implications about this possibly life-saving vaccine.
authors.affiliation: Department of Physiologic Nursing, School of Nursing, University of California, San Francisco, USA. monica.mclemore@ucsf.edu
authors.forename: Monica R
authors.initials: MR
authors.lastname: McLemore
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D017277:Drug Approval; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D052140:Human papillomavirus 11 / Q000276:immunology; D052162:Human papillomavirus 16 / Q000276:immunology; D052161:Human papillomavirus 18 / Q000276:immunology; D052163:Human papillomavirus 6 / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D030361:Papillomavirus Infections / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology; D053918:Papillomavirus Vaccines / Q000009:adverse effects / Q000276:immunology; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration; D002583:Uterine Cervical Neoplasms / Q000821:virology; D014611:Vaccination / Q000379:methods* / Q000451:nursing
chemical_list: D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines